Renal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Renal Cancer Research. Learn more about our innovative pipeline today! @ Renal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Renal Cancer Pipeline Report

* In October 2024:- Hoffmann-La Roche- This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
* In October 2024:- BeiGene- Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma
* In October 2024:- Novartis Pharmaceuticals- The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.
* In October 2024;- Merck Sharp & Dohme LLC- The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.
* In October 2024:- EMD Serono- An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies. The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
* In October 2024:- Peloton Therapeutics Inc.- This open-label Phase 2 study will evaluate the efficacy and safety of belzutifan in participants with VHL disease who have at least 1 measurable RCC tumor. Belzutifan will be administered orally and treatment will be continuous. Participants will be evaluated radiologically approximately 12 weeks after initiation of treatment and every 12 weeks thereafter while continuing in the study for a minimum of 3 years and then every 24 weeks or more frequently if clinically indicated. Changes in VHL disease-associated non-RCC tumors will also be evaluated.
* DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
* The leading Renal Cancer Companies working in the market includes Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd ., and others.
* Promising Renal Cancer Pipeline Therapies in the various stages of development includes Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461 , and others.

Stay informed about the cutting-edge advancements in Renal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Renal Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Renal Cancer Emerging Drugs Profile

* Atezolizumab : Genentech

Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.

* Olaparib: AstraZeneca

Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.

* MK-4830 : Merck & Co., Inc

MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.

* ALLO-316 : Allogene Therapeutics

ALLO-316, an AlloCAR T Trademark investigational product that targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors the drug candidate has received Fast Track Designation (FTD) from U.S FDA based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinoma. The drug is in Phase I stage of clinical trials.

Learn more about Renal Cancer Drugs opportunities in our groundbreaking Renal Cancer Research and development projects @ Renal Cancer Unmet Needs [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical

Renal Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Renal Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Renal Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Renal Cancer Pipeline Report

* Coverage- Global
* Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
* Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461 , and others.

For a detailed overview of our latest research findings and future plans, read the full details of Renal Cancer Pipeline on our website @ Renal Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Renal Cancer Executive Summary
* Renal Cancer: Overview
* Renal Cancer Pipeline Therapeutics
* Renal Cancer Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Atezolizumab: Genentech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Olaparib: AstraZeneca
* Early Stage Products (Phase I)
* Allogene Therapeutics: ALLO-316
* Inactive Products
* Renal Cancer Companies
* Renal Cancer Products
* Renal Cancer Unmet Needs
* Renal Cancer Market Drivers and Barriers
* Renal Cancer Future Perspectives and Conclusion
* Renal Cancer Analyst Views
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=renal-cancer-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.